Axial Spondyloarthritis – Unmet Need – Unmet Need – Ankylosing Spondylitis (US/EU)

Over the past two decades, TNF-α inhibitors (AbbVie’s Humira, Amgen / Pfizer’s Enbrel, Johnson & Johnson Innovative Medicine’s Remicade and Simponi, and UCB’s Cimzia) have significantly reshaped the treatment landscape for AS, bringing greater focus to this autoimmune disease. IL-17 inhibitors (Novartis’s Cosentyx, Eli Lilly’s Taltz, and UCB’s Bimzelx) have further expanded treatment options by offering an alternative mechanism of action. More recently, oral targeted therapies, such as JAK inhibitors (AbbVie’s Rinvoq and Pfizer’s Xeljanz), have also been approved for AS. This report explores the remaining unmet need in AS treatment and highlights commercial opportunities, as well as the potential for emerging therapies to address these gaps.

Questions answered

• What are the treatment drivers and goals for AS?
• Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
• How do current therapies perform on key treatment drivers and goals for AS?
• What are the prevailing areas of unmet need and opportunity in AS?
• What trade-offs across different clinical attributes and price are acceptable to U.S. and European rheumatologists for a hypothetical new AS drug?

Product description

Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:

• Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.

• Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.

• Analyze market scenarios for different target product profiles using the TPP Simulator.

Key feature:

TPP simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European rheumatologists fielded in December 2025

Key companies: AbbVie, Johnson & Johnson Innovative Medicine, UCB, Novartis, Eli Lilly, Pfizer

Key drugs: Humira, Remicade, Cimzia, Cosentyx, Taltz, Xeljanz, Rinvoq